Tuberculosis (TB) lesions are extremely complex and dynamic. Here, we review the multiple
types and fates of pulmonary lesions that form following infection by M ycobacterium …

The timelines for developing vaccines against infectious diseases are lengthy, and often
vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of …

Bacillus Calmette Guérin (BCG) is the only currently available vaccine against tuberculosis
(TB), but it confers incomplete and variable protection against pulmonary TB in humans and …

Tuberculosis (TB) is a leading cause of death worldwide despite the availability of effective
chemotherapy for over 60 years. Although Mycobacterium bovis bacillus Calmette-Guérin …

It is estimated that one-third of the world's population is infected with Mycobacterium
tuberculosis. Infection typically remains latent, but it can reactivate to cause clinical disease …

Tuberculosis (TB) is the leading killer among all infectious diseases worldwide despite
extensive use of the Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccine. A safer …

Non‐human primates (NHPs) are used to model human disease owing to their remarkably
similar genomes, physiology, and immune systems. Recently, there has been an increased …

Nonhuman primates have emerged as an excellent model of human tuberculosis, in large
part because they recapitulate the full spectrum of infection outcome and pathology seen in …

A single intradermal vaccination with MTBVAC given to adult rhesus macaques was well
tolerated and conferred a significant improvement in outcome following aerosol exposure to …

There is an urgent need for an improved TB vaccine. Vaccine development is hindered by
the lack of immune correlates and uncertain predictive value of preclinical animal models …